Description

A study by StrategyHelix indicates that the global natural killer cell therapy market is projected to expand at a CAGR of ~36.8 percent across the forecast period of 2022 – 2028.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for natural killer cell therapy. The global natural killer cell therapy market is segmented on the basis of therapy type, indication, and region. Based on therapy type, the global natural killer cell therapy market is categorized into CAR-NK cell therapy (modified), NK cell engager, NK cell therapy (unmodified). On the basis of indication, the global natural killer cell therapy market has been segmented into acute myeloid leukemia (AML), hepatocellular carcinoma (HCC), peripheral T-cell lymphoma (PTCL), relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). In terms of geography, the global natural killer cell therapy market has been segmented into Asia Pacific, Europe, North America.

The global natural killer cell therapy market is highly competitive. Top players covered in Global Natural Killer Cell Therapy Market Study are Acepodia Inc., Affimed N.V., Celularity Inc., Century Therapeutics Inc., Cytovac A/S, Dragonfly Therapeutics Inc., Fate Therapeutics Inc., Gamida-Cell Ltd., GC Biopharma Corp., Glycostem Therapeutics B.V., iCell Gene Therapeutics LLC, ImmunityBio Inc., Innate Pharma S.A., Nkarta Inc., Sanofi S.A., Senti Biosciences Inc., Shoreline Biosciences Inc., Takeda Pharmaceutical Company Limited, VaxCell Biotherapeutics Co. Ltd. Competitive landscape gives a description of the competitive nature of the global natural killer cell therapy market and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the natural killer cell therapy market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Therapy type: CAR-NK cell therapy (modified), NK cell engager, NK cell therapy (unmodified)
Indication: acute myeloid leukemia (AML), hepatocellular carcinoma (HCC), peripheral T-cell lymphoma (PTCL), relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL)
Region: Asia Pacific, Europe, North America
Years considered: this report covers the period 2018 to 2028
Company mentioned: Acepodia Inc., Affimed N.V., Celularity Inc., Century Therapeutics Inc., Cytovac A/S, Dragonfly Therapeutics Inc., Fate Therapeutics Inc., Gamida-Cell Ltd., GC Biopharma Corp., Glycostem Therapeutics B.V., iCell Gene Therapeutics LLC, ImmunityBio Inc., Innate Pharma S.A., Nkarta Inc., Sanofi S.A., Senti Biosciences Inc., Shoreline Biosciences Inc., Takeda Pharmaceutical Company Limited, VaxCell Biotherapeutics Co. Ltd.

Key Benefits for Stakeholders

– Get a comprehensive picture of the global natural killer cell therapy market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Natural killer cell therapy market overview
Part 3. Market breakdown by therapy type
– CAR-NK cell therapy (modified)
– NK cell engager
– NK cell therapy (unmodified)
Part 4. Market breakdown by indication
– Acute myeloid leukemia (AML)
– Hepatocellular carcinoma (HCC)
– Peripheral T-cell lymphoma (PTCL)
– Relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL)
Part 5. Market breakdown by region
– Asia Pacific
– Europe
– North America
Part 6. Key companies
– Acepodia Inc.
– Affimed N.V.
– Celularity Inc.
– Century Therapeutics, Inc.
– Cytovac A/S
– Dragonfly Therapeutics, Inc.
– Fate Therapeutics, Inc.
– Gamida-Cell Ltd.
– GC Biopharma Corp.
– Glycostem Therapeutics B.V.
– iCell Gene Therapeutics, LLC
– ImmunityBio, Inc.
– Innate Pharma S.A.
– Nkarta, Inc.
– Sanofi S.A.
– Senti Biosciences, Inc.
– Shoreline Biosciences, Inc.
– Takeda Pharmaceutical Company Limited
– VaxCell Biotherapeutics Co., Ltd.
About StrategyHelix
Disclaimer